ACD will be at booth #113 at the Immuno-oncology Summit in Boston, MA. 

Scheduled ACD presentation:

BIOMARKERS TO PREDICT RESPONSE TO IMMUNOTHERAPY Session

Tuesday, August 28 (@ Waterfront Room 1) , 3:00 pm - 3:30 pm

Expanding CDx Strategy Options with RNAscope™, A Clinically-Validated, Quantitative in situ RNA Biomarker Platform 

Presented by: Chris Bunker, PhD, Vice President, Business Development, Advanced Cell Diagnostics

RNAscope is a clinically validated in situ hybridization assay that enables multiplexed tissue expression analysis in routine clinical biopsy tissues. RNAscope is the most sensitive and specific platform for tissue-based expression analysis. It is enabling faster, robust and wide dynamic range tissue-based biomarker expression analysis for accurate correlation to treatment outcome and selection of responsive patient for clinical trial enrollment and CDx.